

1 **Prevalence of antibodies to SARS-CoV-2 in healthy blood donors in New York**

2
3 Kathy Kamath¹, Elisabeth Baum-Jones¹, Gregory Jordan¹, Winston Haynes¹, Rebecca Waitz¹, John Shon¹, Steve
4 Kujawa¹, Lyn Fitzgibbons², Debra Kessler³, Larry Luchsinger³, Yale IMPACT Team⁴, Patrick Daugherty¹

5
6 ¹ Serimmune, Inc., 150 Castilian Dr, Suite 100, Goleta, CA 93117 USA

7 ² Santa Barbara Cottage Hospital, 2400 Bath St., Santa Barbara, CA 93105 USA

8 ³ New York Blood Center 310 East 67th St., New York, NY 10065 USA

9 ⁴ Yale University School of Medicine 60 College St., New Haven, CT 06510 USA

10
11 **Corresponding author: Kathy Kamath**

12 Email: kathy@serimmune.com

13 Telephone: +1 (805) 448-6529

14
15 Members of the Yale IMPACT Team⁴

16 Kelly Anastasio, Michael H. Askenase, Maria Batsu, Santos Bermejo, Kristina Brower, Molly L. Bucklin, Staci Cahill,

17 Melissa Campbell, Yiyun Cao, Arnau Casanovas-Massana, Rupak Datta, Giuseppe Deluliis, Charles Dela Cruz,

18 Rebecca Earnest, Shelli Farhadian, John Fournier, Bertie Geng, Nathan Grubaugh, Ryan Handoko, Akiko Iwasaki,

19 William Khoury-Hanold, Lynda Knaggs, Albert Ko, Maxine Kuang, Sarah Lapidus, Anjelica Martin, Irene Matos,

20 David McDonald, Maksym Minasyan, Adam J. Moore, M. Catherine Muenker, Nida Naushad, Allison Nelson,

21 Jessica Nouws, Angela Nunez, Hong-Jai Park, Xiaohua Peng, Tyler Rice, Kadi-Ann Rose, Lorenzo Sewanan, Lokesh

22 Sharma, Denise Shepard, Mikhail Smolgovsky, Nicole Sonnert, Yvette Strong, Codruta Todeasa, Jordan Valdez,

23 Sofia Velazquez, Pavithra Vijayakumar, Elizabeth B. White, Anne L. Wyllie

24

25 **ABSTRACT**

26 Despite the high level of morbidity and mortality worldwide, there is increasing evidence for asymptomatic
27 carriers of the novel coronavirus SARS-CoV-2. We analyzed blood specimens from 1,559 healthy blood donors,
28 collected in the greater New York metropolitan area between the months of March and July 2020 for antibodies
29 to SARS-CoV-2 virus. Using our proprietary technology, SERA (Serum Epitope Repertoire Analysis), we observed a
30 significant increase in SARS-CoV-2 seropositivity rates over the four-month period, from 0% [95% CI: 0 - 1.5%]
31 (March) to 11.6% [6.0 - 21.2%] (July). Follow-up ELISA tests using S1 and nucleocapsid viral proteins confirmed
32 most of these results. Our findings are consistent with seroprevalence studies within the region and with reports
33 that SARS-COV-2 infections can be asymptomatic or cause only mild symptoms.

34

35 **IMPORTANCE**

36 The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has caused vast morbidity and mortality
37 worldwide, yet several studies indicate that there may be a significant number of infected people who are
38 asymptomatic or exhibit mild symptoms. In this study, samples were collected from healthy blood donors in a
39 region of rapidly increasing disease burden (New York metropolitan area) and we hypothesized that a
40 subset would be seropositive to SARS-CoV-2. People who experienced mild or no symptoms during SARS-CoV-2
41 infection may represent a source for convalescent plasma donors.

42

43 **OBSERVATION**

44 The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has exerted high morbidity worldwide,
45 with mortality rates reported greater than 10% for some age groups [1]. Yet several studies have indicated that
46 there may be a significant number of people who are asymptomatic or exhibit mild symptoms [2 - 4], including in
47 the New York metropolitan region [5, 6]. We developed an assay to detect IgG and IgM antibodies to SARS-CoV-

48 2 virus and analyzed plasma samples from healthy blood donors collected during the early months of the
49 pandemic in that region.

50

51 **Development of SERA assay for antibodies to SARS-CoV-2**

52 Our technology, Serum Epitope Repertoire Analysis (SERA) enables discovery and semi-quantitative detection of
53 antibody epitopes with high resolution that can be mapped to eliciting antigens and organisms. The SERA assay
54 platform has been described in detail elsewhere [7], but briefly, it utilizes a random bacterial display 12-mer
55 peptide library of 10^{10} diversity in conjunction with NGS to collect and sequence the set of peptides that represent
56 an individual's serological antibody epitope repertoire. The shared epitopes targeted by antibody repertoires are
57 then identified by custom bioinformatics algorithms [8], using cohort-based subtractive analysis of the mimotope
58 repertoires. For the development of SERA panels to detect IgG and IgM antibodies against SARS-CoV-2, serum
59 samples from confirmed COVID-19 patients (positive for SARS-CoV-2 nucleic acid testing (NAT)) were acquired
60 from the Yale IMPACT biorepository and the Santa Barbara Cottage Hospital (Santa Barbara, CA) in accordance
61 with BRISQ guidelines [9] and the SBCH IRB. The majority of subjects were hospitalized and serum samples were
62 collected between 0 and 57 days post symptom onset. For the discovery of SARS-CoV-2 IgG and IgM antibody
63 epitope motifs, we applied SERA to a Discovery cohort of 164 COVID-19 samples, and 430 (for IgM panel) and 497
64 (for IgG panel) pre-pandemic healthy controls (**Table S1**). The resulting epitope motifs were compiled into IgG and
65 IgM panels, and the enrichment of each panel motif was normalized and summed to generate a composite
66 diagnostic score [7]. A seropositivity cut-off value of 25 was established to yield a specificity of > 99% for either
67 panel. In an independent verification set of 250 COVID-19 specimens for which we had days since symptom onset
68 data, the sensitivity of SERA IgG and IgM at >10 days post symptom onset was $\geq 91\%$ (**Figure 1**). In a cohort of
69 1,500 pre-pandemic samples, the specificity of the SERA SARS-CoV-2 IgG panel was 99.3% and the IgM panel was
70 99.1%; the specificity of the IgG and IgM panels together was 98.7%.

71

72 **Sample collection from healthy blood donors**

73 We initiated a collaboration with Blood Centers of America to collect plasma from healthy donors throughout the
74 US with a primary objective of increasing our healthy subject cohort. Collection and screening began in New York
75 at the New York Blood Center (NYBC) in March 2020. Individuals who were suspected of having COVID-19 were
76 deferred from donation for 14 days after resolution of symptoms. For this study, a total of 1,559 whole blood
77 samples from healthy blood donors were sent to our laboratory within 2 weeks of collection, in seven shipments.
78 The demographics of these samples are shown in **Table S2**. Upon arrival at our laboratory, blood plasma was
79 isolated, screened by SERA assay and the results were uploaded to the epitope repertoire database.

80

81 **Prevalence of antibodies to SARS-CoV-2 in blood donors**

82 For each sample analyzed using the SERA assay, the epitope repertoires are compiled into a database that enables
83 assessment of any previously or future developed disease-specific SERA panel, without the need to re-test the
84 sample. We applied the SARS-CoV-2 IgG panel retrospectively to samples collected during the
85 period March 1 through July 7, 2020. Of 1,559 blood samples processed, a total of 68 had IgG antibodies against
86 SARS-CoV-2 on the SERA assay. As collection proceeded, the seropositive rate increased from 0% [95% CI: 0 -
87 1.5%] to 11.6% [6.0 - 21.2%] (**Figure 2, Table S3**). Eighty-four percent (57/68) of these samples were also positive
88 for IgG antibodies to SARS-CoV-2 Spike S1 and nucleocapsid proteins by follow-up ELISAs (**Supplemental Text 1**),
89 providing independent verification of the presence of a SARS-CoV-2 antibody response in these subjects.

90

91 Because the age of donors were not equally distributed amongst the sample shipments, we interrogated whether
92 age or shipment date was a stronger predictor of the seropositivity observed. GLM regression analysis of SARS-
93 CoV-2 seropositivity relative to donor age or shipment date revealed that sample shipment date contributed more
94 significantly ($p=5.5e-8$) to the prediction of seropositivity than age ($p=0.35$) (**Supplemental Figure 1**).

95

96 **Concluding remarks**

97 This study provides insight into trends of rate of seropositivity to SARS-CoV-2 among asymptomatic blood donors
98 in the metropolitan New York area during the early months of the COVID-19 pandemic but was not designed to
99 measure population-wide seroprevalence. Nonetheless, our results were consistent with reports that a significant
100 number of SARS-CoV-2 infected people in this region may be asymptomatic or present with mild symptoms [5, 6].

101
102 Here we demonstrated the utility of SERA for serosurveillance studies of emerging infections through
103 retrospective analysis of archived data in populations. Previously collected data was simply re-analyzed for SARS-
104 CoV-2 associated epitopes, thus mitigating the need to store samples or perform additional assays in a surveillance
105 setting. In addition, the new panel was applied retrospectively *in silico* to large pre-pandemic cohorts in panel
106 development and verification phases, demonstrating high specificity without the need to perform additional
107 immunoassays. Finally, applying the panel to cohorts afforded the opportunity to identify subjects with
108 presumptive asymptomatic or mild disease for research purposes amongst the blood donor population from New
109 York and surrounding areas.

110
111 Our results raise the question of whether a larger number of convalescent plasma donors could be identified
112 among healthy, asymptomatic donors. However, there is concern about providing antibody results to blood
113 donors without an improved understanding of their immunological significance. We also demonstrate the utility
114 of SERA for monitoring the antibody response to emerging infections.

115
116
117

REFERENCES


- 118 1. Petersen E, Koopmans M, Go U, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics.
119 **Lancet Infect Dis.** 2020 ; 20:e238-e244

- 120 2. Nishiura H, Kobayashi T, Miyama T, et al. Estimation of the asymptomatic ratio of novel coronavirus
121 infections (COVID-19). **Int J Infect Dis.** 2020 ; 94:154-155
- 122 3. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus
123 disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. **Euro**
124 **Surveill.** 2020 ; 25:2000180
- 125 4. Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United
126 States, March 23-May 12, 2020 [published online ahead of print, 2020 Jul 21]. **JAMA Intern Med.** 2020 ;
127 10.1001/jamainternmed.2020.4130. doi:10.1001/jamainternmed.2020.4130
- 128 5. Rosenberg ES, Tesoriero JM, Rosenthal EM, et al. Cumulative incidence and diagnosis of SARS-CoV-2
129 infection in New York [published online ahead of print, 2020 Jun 17]. **Ann Epidemiol.** 2020 ; S1047-
130 2797(20)30201-5
- 131 6. Stadlbauer D, Tan J, Jiang K, Hernandez MM, Fabre S, Amanat F, Teo C, Arunkumar GA, McMahon M,
132 Jhang J, Nowak MD, Simon V, Sordillo EM, van Bakel H, Krammer F. Seroconversion of a city: Longitudinal
133 monitoring of SARS-CoV-2 seroprevalence in New York City. MedRxiv. [Preprint] July 28, 2020. Available
134 from <https://doi.org/10.1101/2020.6.28.20142190>
- 135 7. Kamath K, Reifert J, Johnston T, et al. Antibody epitope repertoire analysis enables rapid antigen discovery
136 and multiplex serology. **Sci Rep.** 2020 ; 10:5294
- 137 8. Pantazes RJ, Reifert J, Bozekowski J, Ibsen KN, Murray JA, Daugherty PS. Identification of disease-specific
138 motifs in the antibody specificity repertoire via next-generation sequencing. **Sci Rep.** 2016 ; 6:30312.
- 139 9. Moore HM, Kelly AB, Jewell SD, et al. Biospecimen reporting for improved study quality (BRISQ). **J**
140 **Proteome Res.** 2011 ; 10:3429-3438

141
142
143

144 **FIGURES**


145 **Figure 1**



146


147

148 **Figure 2**



149

150 **Figure S1**



151

152

153

154 **FIGURE LEGENDS**

155

156 **Figure 1: Performance SERA assay to detect IgG and IgM antibodies to SARS-CoV-2.** SERA IgG+IgM performance
157 on a validation cohort of SARS-CoV-2 NAT+ patients. The maximum SERA score for IgG or IgM is shown. Samples
158 above a cutoff of 25 are classified as seropositive. COVID-19 cases are indicated by days post symptom onset.
159 Panel sensitivity at the specified time intervals are shown above each group. Specificity on a cohort of 1,500 pre-
160 pandemic controls was 99.3% for IgG, 99.1% for IgM, 98.7% for IgG or IgM, and 100% if a case was positive for IgG
161 and IgM (no pre-pandemic validation controls were positive for both IgG and IgM concomitantly).

162

163 **Figure 2. Seropositivity rate of SARS-CoV-2 based on SERA IgG increases over time in healthy, asymptomatic**
164 **blood donors.** A) SERA SARS-CoV-2 IgG scores and B) percentage of samples that were SARS-CoV-2 IgG positive

165 from healthy blood donors by shipment date. Error bars in (B) represent 95% CI using Wilson score. Shipment
166 dates are shown on the x-axis; blood samples were collected within 2 weeks prior to shipment. Each shipment
167 included 245-250 subjects except the final shipment (n = 69).

168

169 **Supplemental Figure S1: SARS-CoV-2 seropositivity vs. shipment date for each specimen.** GLM regression
170 analysis of seropositivity to SARS-CoV-2 relative to the age of the patient and the shipment date of the sample.
171 Shipment date contributed more significantly ($p=5.5e-8$) to the prediction of seropositivity than age ($p=0.35$).
172 When we performed the same regression for SARS-CoV-2 seropositivity against age alone, the age coefficient was
173 significant ($p=5.5e-5$). Similarly, regression for SARS-CoV-2 seropositivity against shipment date alone yielded a
174 highly significant shipment date coefficient ($p=1.0e-9$). These results suggest that shipment date, not the age bias,
175 is the dominant factor contributing to the increased positivity rates.

176

177

178 **SUPPLEMENTAL MATERIALS**

179

180 **Supplemental Text 1: Spike and Nucleocapsid protein ELISA.** For confirmatory ELISA testing, 50 μ L of SARS-CoV-
181 2 Spike S1 or nucleocapsid recombinant proteins (ACROBiosystems cat# S1N-C52H3 and NUN-C5227) were coated
182 on ELISA plates at 0.5 μ g/mL. Plates were blocked with 5% nonfat dry milk (NFDM) in PBS followed by incubation
183 with plasma diluted 1:250 in PBS. Wells were washed 3X with PBS with 0.1% tween20 (PBST) and incubated with
184 anti-human IgG conjugated to HRP (Jackson Immuno Research labs cat# 109-035-088) at 1:10,000. Wells were
185 washed 4X with PBST and developed with TMB solution. Cut-off values for ELISAs were established based on 400
186 pre-pandemic controls.

187

188

189

190

191 **Table S1: Sample cohorts for discovery and verification of SARS-CoV-2 epitope motif panels**

	Sample Cohort	COVID-19 Disease Severity				Total n
		Asymp	Mild/ Moderate	Severe	Moderate or Severe*	
Discovery Set	Confirmed COVID-19 (Yale IMPACT)	5	103	45	11	164
	Pre-pandemic controls	-	-	-	-	430 (IgM) or 497 (IgG)
Verification Set	Confirmed COVID-19 (Yale IMPACT)	8	20	17	143	191
	Confirmed COVID-19 (SBCH)	4	54	22	-	81
	Mayo Clinic pre-pandemic controls	-	-	-	-	1,500

192 *Subjects were hospitalized but intubation status was not known

193

194

195 **Table S2: Demographics of Healthy Blood Donors**

Donor characteristics		n	%
Sex	Female	755	48
	Male	804	52
Age	17-25	395	25
	26-35	200	13
	36-45	164	11
	46-55	206	13
	56-65	370	24
	66-80	224	14
Race	White	396	25
	Black	350	22
	Hispanic/Latino	454	29
	Asian/Pacific Islander	358	23
	Other	1	0.1

196

197

198

199

200

201

202

203 **Table S3. Blood donor samples analyzed and prevalence of seropositive samples per shipment**
204

Shipment Date	Number of Samples in Shipment	Number of Seropositive Samples	Proportion of Seropositive Samples (95% CI)
3/12/2020	250	0	0% (0 - 1.5%)
3/26/2020	250	2	0.8% (0.2 - 2.9%)
4/16/2020	249	5	2.0% (0.9 - 4.6%)
5/28/2020	247	15	6.1% (3.7 - 9.8%)
6/10/2020	249	20	8.0% (5.3 - 12.0%)
6/24/2020	245	18	7.3% (4.7 - 11.3%)
7/9/2020	69	8	11.6% (6.0 - 21.2%)
All shipments	1,559	68	

205
206

207
208
209

FOOTNOTE PAGE

210 **Conflict of interest statement**

211 Serimmune employees (K.K., E.B.J., G.J., W.H., R.W., J.S., S.K., P.D.) receive salary and stock options from
212 Serimmune.

213

214 **Funding statement**

215 SARS-CoV-2 sample collection and curation by the Yale IMPACT team was supported by the Yale COVID-19
216 resource research fund.